Akesis Biologics, a biotechnology spinoff from the National University of Singapore (NUS), has unveiled MastGut, a groundbreaking supplement designed to enhance gut and colorectal health. This innovative product employs the DUSP10 enzyme, delivered via the probiotic Lactococcus lactis, to reduce gut inflammation and support long-term colorectal health. With colorectal cancer being the second leading cause of cancer-related deaths globally, MastGut aims to address this pressing health issue.
MastGut distinguishes itself from traditional supplements by using a scientific approach grounded in academic research. “Most people think of probiotics as general digestive aids,” said Zhang Yongliang, co-founder and CEO of Akesis. “MastGut takes it much further. We intend to deliver an active functional protein that regulates inflammation and suppresses tumour-promoting enzyme activities—all using a probiotic vehicle.”
The DUSP10 enzyme acts as a brake on the MAPK pathway, a molecular signal chain often overactivated in gut inflammation and cancer. Studies have shown that higher expression of DUSP10 in humans is linked to better colorectal cancer outcomes. “This isn’t just another supplement,” said Chin Wen Png, co-founder and CTO of Akesis. “MastGut sits at the intersection of therapeutic treatment and nutritional science.”
Akesis Biologics is actively collaborating with hospitals, pharmacies, and research partners to expand MastGut’s reach across Asia and beyond. Associate Professor Benjamin Tee, Vice President of Ecosystem Building at NUS Enterprise, highlighted the significance of this launch, stating, “Akesis Biologics’ successful journey from lab to market exemplifies our ongoing commitment to nurturing deep tech ventures and empowering them to create meaningful societal impact.”
“`
